-
Light-exacerbated pain occurring during migraine headaches is associated with increased cerebral blood flow in the visual cortex. This activation of retinal ganglion cells by light, present even in blind migraineurs, occurs through posterior thalamic connections.
-
Neurosurgical interventions for trigeminal neuralgia have never been rigorously studied for efficacy and carry significant risks.
-
Non-Hodgkin B-cell lymphomas are more likely to be associated with peripheral nerve disorders, and Hodgkin's disease with central nervous system syndromes.
-
-
-
In this issue: Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
Exertional heat-related injuries are on the rise in EDs, with an estimated 54,000 patients treated over a 10-year period a 133% increase that was not linked to increased seasonal temperatures, according to a new study.
-
Dosages based on the color-coded Broselow Pediatric Emergency tape will soon be displayed on a large LCD monitor for all ED staff to see, says Andre A. Muelenaer Jr., part of the product's developmental team and an associate professor of pediatrics at the Virginia Tech Carilion School of Medicine in Roanoke.
-
Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
The optimal standard salvage therapy for relapsed or refractory AML remains undetermined. The authors retrospectively compared two regimens at a single institution: CLAG (cladribine, high-dose cytarabine, and G-CSF) with MEC (mitoxantrone, etoposide, and cytarabine). These observational data without adjustment suggest CLAG may be superior to MEC. Nevertheless, outcomes for relapsed or refractory AML remain poor and clinical trials should be entertained when available.